LECT2

Across TCGA pan-cancer cohorts, LECT2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LECT2 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LECT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LECT2 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LSCC, GBM, and CCRCC are the cancer types where LECT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.834	1.000	.003	17	view →
GBM	OS	Median	All	1.000	0.285	.004	6	view →
CCRCC	OS	Median	IV	1.000	0.451	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LECT2–LSCC (DFS)

Open the LSCC breakdown →